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Summary
Systemic lupus erythematosus (SLE) is characterized
by the production of autoantibodies that are frequently
directed against nucleic acid-associated antigens. To
better understand how B cells reactive with such anti-
gens are regulated, we generated a model system
in which heavy and light chain genes encoding 564
immunoglobulin have been targeted to the heavy and
light chain loci of the nonautoimmune C57BL/6 mouse
strain. This antibody recognizes RNA, single-stranded
DNA, and nucleosomes.We show that B cells express-
ing this immunoglobulin were activated, producing
class-switched autoantibody in vivo despite the
apparently normal induction of anergy. This autoanti-
body productionwas largely dependent on Toll-like re-
ceptor 7 (TLR7). We further show that production of
these autoantibodies was sufficient to cause kidney
pathology in these mice. These results demonstrate
that the particular threat of nucleic acid-containing
autoantigens lies in their ability to bind both antigen
receptor and TLR7.
Introduction
Toll-like receptors (TLRs) are pattern-recognition recep-
tors that bind to molecular structures associated with
pathogens and alert the immune system to the presence
of infection (Takeda et al., 2003). The TLR family has 11
recognized members. Most TLR ligands, such as lipo-
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7 Present address: Emory University School of Medicine, Atlanta,
Georgia 30322.polysaccharide (LPS, recognized by TLR4), flagellin
(recognized by TLR5), and bacterial lipoproteins and
lipoteichoic acids (recognized by TLR2), are unique to
pathogens. In contrast, TLR7 and TLR9 recognize sin-
gle-stranded RNA (ssRNA) and double-stranded DNA
(dsDNA), respectively, which are present in the host as
well (Takeda et al., 2003). Activation of these receptors
by host nucleic acid is avoided, in large part, by their in-
tracellular localization (Barton et al., 2006; Heil et al.,
2004). However, recent in vitro experiments have dem-
onstrated that if host DNA or RNA is delivered to the
appropriate compartment by receptor-mediated endo-
cytosis, activation results, as measured by either cellular
proliferation in the case of B cells (Lau et al., 2005; Lead-
better et al., 2002; Viglianti et al., 2003) or cytokine
production in the case of dendritic cells (DC) or plasma-
cytoid dendritic cells (pDC) (Boule et al., 2004; Vollmer
et al., 2005). This provides a potential mechanism for
the activation of B cells expressing a B cell receptor
(BCR) reactive with nucleic acid-containing antigens
such as nucleosomes or Smith antigen ribonucleopro-
tein (SmRNP). These ‘‘dual specificity’’ antigens could
potentially activate autoreactive B cells as a result of
their ability to ligate both the BCR and, after endocyto-
sis, either TLR9 or TLR7. B cells reactive with such
antigens are commonly generated as a result of random
recombination of V(D)J gene segments during B cell de-
velopment (Wardemann et al., 2003) and may also arise
in the periphery as a result of hypermutation in germinal
centers. A variety of B cell tolerance mechanisms are
believed to prevent these cells from becoming activated
under normal circumstances (Goodnow et al., 2005).
In order to better understand how B cells reactive with
nucleic acid-containing antigens are regulated in non-
autoimmune-prone mice, we have generated a new
site-directed immunoglobulin transgenic mouse line,
564Igi. The V(D)J used in 564 Igi mice was cloned from
a hybridoma derived from an autoimmune SWRxNZB
(SNF1) mouse (Gavalchin et al., 1987). It produces
a pathogenic (Vlahakos et al., 1992) polyreactive anti-
body that reacts with ssDNA (Gavalchin et al., 1987),
ssRNA (Gavalchin et al., 1987), and nucleosomes
(Mohan et al., 1993). Several other Ig-transgenic mouse
lines have been generated with BCRs specific for nu-
cleic acid or other specificities commonly recognized
by autoantibodies in patients with SLE (reviewed in
Fields and Erikson, 2003). These include anti-dsDNA,
anti-ssDNA, anti-Sm, and Rheumatoid Factor (RF). De-
pending on the model system, the general result is
that, on nonautoimmune backgrounds, the production
of immunoglobulin G (IgG) autoantibodies is prevented
by either Ig receptor editing, deletion, induction of B cell
anergy, or, in the case of anti-Sm, differentiation to the
B-1a population (Fields and Erikson, 2003). As in these
other systems, in the present study 564-expressing B
cells underwent receptor editing, resulting in a large
fraction of 564-negative cells. Those cells that retained
the 564Igi idiotype were anergic based on their surface
phenotype, exclusion from the marginal zone (MZ),
and lack of response to BCR crosslinking or LPS in vitro.
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430Figure 1. Receptor Editing in 564Igi Mice
(A) Specificity of the B6-256 (anti-Id) monoclonal antibody. Splenocytes from a nontransgenic C57BL/6 mouse, a mouse heterozygous for the 564
heavy chain (564H), and a mouse expressing both heavy and light chains of 564 (564HL) were stained with B6-256 and antibodies against m, ma, or
mb and analyzed by flow cytometry. Viable (PI-excluding) lymphocytes are shown. The percentage of cells in each quadrant is indicated.
(B) Effect of RAG2 deficiency on the frequency of Id+ splenocytes. Splenocytes from mice of the indicated genotypes were stained as indicated
and analyzed by flow cytometery. Viable lymphocytes are shown. Percentages of cells in each gate are shown.
(C) Endogenous l light chain gene expression in 564Igi mice. Splenocytes from 564Igi-Rag22/2 and 564Igi-Rag2+/+ mice were stained with
B6-256 anti-Id, anti-CD45 (B220), and anti-l light chain and analyzed by flow cytometry. Histograms are gated on viable B220+ lymphocytes
that were either Id+ or Id2 as indicated. All results are representative of at least three independent experiments.Strikingly, despite this induction of anergy, we found
considerable amounts of 564 idiotype-positive TH1-
skewed IgG antibody in the serum of 564Igi mice. Pro-
duction of these antibodies was largely dependent on
TLR7. This represents the first in vivo evidence that
TLR7 can drive the production of nuclear antibodies.
We were also able to detect evidence of kidney pathol-
ogy in mice producing these autoantibodies. This pa-
thology was similar to what is seen in SLE-associated
kidney disease in humans.
Results
Construction of 564Igi Mice
Mice carrying a targeted insertion of the 564 V(D)J have
been described elsewhere (Fernandez, 2001). The gen-
eration of mice carrying a targeted insertion of the 564
light chain is shown in Figure S1 in the Supplemental
Data available online. Mice carrying either the targeted
heavy or light chain locus were backcrossed to
C57BL/6 mice by means of a speed congenic procedure
(Wakeland et al., 1997) for more than 10 generations as
described and then intercrossed to generate mice with
targeted insertions at both loci.Receptor Editing and Anergy in 564Igi Mice
We expected that expression of 564 heavy and light
chains would result in B cell tolerance on the nonauto-
immune C57BL/6 background as a result of receptor
editing (Casellas et al., 2001; Chen et al., 1997) and/or
clonal anergy (Chen et al., 1997; Goodnow et al., 2005).
To determine whether receptor editing occurs in the
564Igi system, we stained splenocytes with an anti-idi-
otype antibody. This antibody stained B cells only in
mice containing targeted insertions of both the heavy
and light chain genes of the 564 antibody (Figure 1A).
Furthermore, only B cells expressing the transgene-de-
rived heavy chain (a allotype) were stained (Figure 1A).
Consistent with receptor editing, a substantial fraction
of B cells in heavy plus light chain insertion mice ex-
pressed endogenous (b allotype) heavy chains and
only a minority of cells expressing the a allotype 564
heavy chain were idiotype positive (Id+) (Figure 1A).
To confirm that the absence of Id+ cells was due to
secondary rearrangements of endogenous Ig genes,
we examined 564Igi mice on a RAG2-deficient
(Rag22/2) background. On this background, essentially
all B cells were 564 Id+ (Figure 1B). Consistent with ex-
tensive editing in RAG2-sufficient 564Igi mice, lambda
light chain was expressed on many Id2 B cells
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431Figure 2. B Cells in 564Igi Mice Were Anergic
(A) Flow cytometry analysis of expression of the indicated surface markers on Id+ (solid lines) or Id2 (dotted lines) splenic B cells from a 564Igi
mouse and, where indicated, on splenic B cells from a nontransgenic C57BL/6 mouse (shaded histograms).
(B) 564Igi Id+ cells were excluded from splenic B cell follicles and MZs. Frozen spleen sections from a nontransgenic C57BL/6 and a 564Igi mouse
were stained with anti-IgM (red), B6-526 anti-id (green), and MOMA (blue).
(C) 564Igi B cells failed to flux calcium in response to BCR crosslinking. Indo-1-loaded RBC-depleted splenocytes from a nontransgenic C57BL/6
mouse (solid lines) and a 564Igi-Rag22/2mouse (dotted lines) were stained with anti-CD45 (B220) and stimulated with 10, 30, or 60 mg/ml of anti-
IgM. Calcium flux was monitored on B220+ cells by flow cytometry. Although anti-IgM concentration is not indicated for the 564Igi samples, three
essentially identical tracings, corresponding to the three different anti-IgM concentrations, are shown.
(D) 564Igi B cells respond poorly to LPS. RBC-depleted splenocytes from a nontransgenic C567BL/6 mouse and a 564Igi-Rag22/2 mouse were
loaded with CFSE and cultured for 3.5 days with or without LPS. Cells were stained with B220 and CFSE fluorescence of viable (PI-excluding)
B220+ cells determined by flow cytometry. All results are representative of at least three independent experiments.(Figure 1C). There was also a fraction of Id+ cells ex-
pressing lambda light chain (Figure 1C).
In other systems, peripheral autoreactive B cells that
fail to edit become anergic (Goodnow et al., 2005). We
therefore examined Id+ B cells for features of anergy
as shown in Figure 2A. Id2 B cells (dotted histograms)
stained similarly to C57BL/6 B cells (shaded histo-
grams). Id+ B cells had reduced surface expression of
CD21/CD35, CD22, and IgD along with increased ex-
pression of CD93 (493, Figure 2A), consistent with devel-
opmental arrest at an immature stage (Fields and Erik-
son, 2003; Phan et al., 2003). 564 Id+ cells also had the
reduced expression of IgM and increased expression
of CD5 that are additional features of anergic B cells
(Fields and Erikson, 2003; Hippen et al., 2000; Phan
et al., 2003; Yachimovich et al., 2002).Anergic B cells are excluded from B cell follicles and
the MZ in the spleen (Cyster et al., 1994; Fields and Erik-
son, 2003). Figure 2B shows a spleen section from
a 564Igi mouse stained with anti-Id (green), anti-IgM
(red), and MOMA (blue). Consistent with their anergic
surface phenotype, 564 Id+ cells were located predomi-
nantly at the T-B border and were mostly absent from
the follicle and MZ.
In some cases, autoreactive B cells become seques-
tered in the peritoneum as B-1 cells (Murakami et al.,
1992; Qian et al., 2001). We found no 564 Id+ B-1 cells
in the peritonea of 564Igi mice (data not shown).
We next examined the ability of 564 Id+ B cells to flux
calcium in response to BCR crosslinking in vitro
(Figure 2C). In this experiment, we used splenocytes
from a 564Igi mouse that was RAG2 deficient, because
Immunity
432Figure 3. 564 Antibody in the Serum of 564Igi Mice
(A) ELISA assay of serum 564 Id+ antibody. Serum from either a nontransgenic C57BL/6 (IgHb) or a 564Igi mouse was diluted as indicated and Id+
antibodies of the indicated isotypes measured by ELISA. Sera of 3–5 mice of each genotype were tested. Mean OD6 SD is presented. There was
no signal above background when our anti-IgG2a reagent was used to detect binding of BALB/c (IgHa) in the ELISA (data not shown). The
dilutions of the 564 hybridoma supernatant correspond to 12, 1.2, 0.12, and 0.012 mg/ml.
(B) Serum antibody in 564Igi mice was autoreactive. Sera from mice of the indicated genotypes were diluted as indicated and used to stain fixed
HEp-2 cells. For comparison, HEp-2 cells were stained with 564 hybridoma supernatant. Results are representative of at least three independent
experiments.all B cells from this mouse were 564 Id+. As a control
we used splenocytes from a nontransgenic C57BL/6
mouse. Cells were loaded with the calcium-sensitive
dye Indo-1, stained with anti-B220, and activated with
different concentrations of F(ab0)2 anti-IgM (anti-IgM).
Calcium fluxes were measured in gated B220+ cells by
flow cytometry. 564Igi B cells did not flux calcium at
any of the doses of anti-IgM used (Figure 2C). As in other
systems (Gauld et al., 2005; Healy et al., 1997), 564Igi B
cells exhibited elevated basal intracellular calcium. This
suggests that 564Igi B cells were continuously exposed
to antigen in vivo (Gauld et al., 2005).
Anergic B cells in some transgenic models are refrac-
tory to activation by bacterial LPS (Fields and Erikson,
2003). To see whether 564Igi B cells could be stimulated
by this mitogen, splenocytes from a nontransgenic
C57BL/6 or a RAG2-deficient 564 Igi mouse were loaded
with carboxyfluorescein diacetate succinimidyl ester
(CSFE) and cultured for 3.5 days with or without LPS.
Figure 2D shows that 564Igi B cells responded very
poorly to LPS.
Taken together, these data show that 564Igi B cells
underwent receptor editing or became anergic (as mea-
sured by multiple criteria), suggesting that tolerance
induction is normal in 564Igi mice.
Serum 564 Antibody in 564Igi Mice
We next measured amounts of serum Id+ antibody in
564Igi mice by using an enzyme-linked immunosorbantassay (ELISA) (Figure 3A). Unexpectedly, we found high
amounts of IgG2a and IgG2b Id+ antibody. Id+ IgM was
also detected in low amounts.
To confirm that the Id+ antibody in the serum retained
the specificity of the original 564 antibody, we per-
formed immunofluorescent staining of fixed human
HEp-2 cells by using anti-mouse IgG as the secondary
reagent (Figure 3B). HEp-2 cell staining was minimal
with control serum from a C57BL/6 nontransgenic
mouse (Figure 3B, left). Antibody purified from the 564
hybridoma stained nucleoli and the cytoplasm (Fig-
ure 3B, second panel). The same staining pattern was
seen with serum from a 564Igi mouse (Figure 3B, third
panel). This staining pattern differs from that seen with
sera from an autoimmune MRL-lpr mouse, which dis-
plays uniform nuclear binding (Figure 3B, right).
These results indicate that despite the apparently
normal induction of B cell anergy, class-switched auto-
antibodies were produced in 564Igi mice.
Kidney Pathology in 564Igi Mice
To determine whether the presence of 564 Id+ anti-
bodies in the sera of 564Igi mice was sufficient to lead
to kidney pathology, we stained frozen sections of kid-
neys from a 1-year-old nontransgenic C57BL/6 mouse
and from three 13-month-old 564Igi mice with fluores-
cently labeled anti-564 Id (Figure 4, left) or anti-mouse
IgG2a (Figure 4, middle). The C57BL/6 kidney sections
failed to stain with either antibody (Figure 4). In contrast,
TLR7-Dependent Loss of Tolerance in Normal Mice
433Figure 4. Kidney Pathology in 564Igi Mice
Deposition of 564 Id+ in kidneys and kidney
pathology in 564Igi mice (left and middle).
Immunofluorescent staining of frozen kidney
sections stained with either anti-564 Id (left)
or anti-mouse IgG2a (middle). 564Igi #1, 2,
and 3 are three different mice. Magnification
is 4653. (Right) Electron micrographs of
kidney sections from the indicated mice.
Magnifications are 33073 for C57BL/6 and
564Igi #1 and 67653 for 564Igi #2 and #3.kidney sections from all three 564Igi mice stained with
both antibodies. This indicated that IgG2a 564 Id+ anti-
bodies were deposited in the kidneys of 564Igi mice.
To more definitively document the presence of kidney
pathology, kidney sections were examined by electron
microscopy (EM) (Figure 4, right, and Figure S2A). By
EM, kidneys from 564Igi mice #1 and #2 showed
changes consistent with those seen in mesangioproli-
ferative glomerulonephropathies in human patients,
which are associated with class 2 lupus nephritis. EM
examination of the kidney from mouse #3 (Figure 4)
revealed less extensive pathology, consistent with the
changes seen in focal and segmental mesangioprolifer-
ative glomerulonephropathies in human patients. The
C57BL/6 mouse had normal kidney architecture by EM
(Figure 4). Light microscopy was consistent with the
EM results (Figure S2B). A more detailed pathology
report is provided in Supplemental Results as is larger
version of the electron micrograph of mouse #1 shown
in Figure 4 (Figure S2A).
These results indicate that the production of 564 anti-
body, in the absence of any other genetic predisposition
to SLE, was sufficient to result in kidney pathology in
564Igi mice.
Serum 564 Antibody in 564Igi Mice
on a RAG2-Deficient Background
The presence of 564 Id+ antibody in the serum could
have been a consequence of allelic inclusion, whereby
a cell expressing 564 heavy and light chains rearranged
an endogenous immunoglobulin heavy or light chain, re-
sulting in the expression of two different immunoglobu-
lin molecules. This might lower the surface density of
564 antibody sufficiently to allow escape from anergy
or deletion (Liu et al., 2005). To test this possibility, we
measured total serum antibodies in 564Igi-Rag22/2
mice where allelic inclusion was not possible. In these
mice, all antibody produced will be 564 Id+. Lack of
RAG2 had no effect on the number of B cells in 564Igimice (data not shown), consistent with results in a differ-
ent anti-ssDNA heavy and light chain knockin mouse (Xu
et al., 1998). In the serum of 564Igi-Rag22/2 mice, there
were considerable titers of total IgM, IgG2a, IgG2b,
IgG3, and IgA (Figure 5A). Strikingly, there was no de-
tectable antibody of the TH2-associated IgG1 or IgE iso-
types. As a negative control, we included serum from an
activation-induced cytidine deaminase (AID)-deficient
(Aicda2/2) mouse that was incapable of class switching.
In an independent experiment to determine the effect of
RAG2 deficiency specifically on the amounts of Id+ anti-
body, we measured Id+ antibodies in the sera of 564Igi-
Rag22/2 and 564Igi-Rag2+/2 mice (Figure S3A). Id+ IgM,
IgG3, and IgG2b were unaffected by the absence of
RAG2, while Id+ IgG2a and IgA were present at 25% to
50% of the amounts detected in 564Igi-Rag2+/2 mice.
Similarly, in 564Igi-Rag22/2 mice, the amounts of
IgG2a cytoplasmic and nucleolar antibodies were 25%
to 50% of the amounts in 564Igi-Rag2+/2 mice as mea-
sured by binding to HEp-2 cells (Figure S3B).
564Igi B cells on the RAG2-deficient background re-
tained the surface phenotype of anergic B cells with
the exception of altered CD22 expression (Figure 5B)
and, as shown above, were refractory to activation by
anti-IgM or LPS (Figures 3C and 3D, respectively).
Thus, allelic inclusion was not responsible for the
production of autoantibodies in 564Igi mice.
564Igi B Cells Were Hyperresponsive
to Activation by CpG
The serum antibodies produced in 564Igi-Rag22/2 mice
were skewed toward TH1-associated isotypes and had
no detectable IgG1 or IgE. These are the isotypes in-
duced by CpG treatment of B cells in vitro (Lin et al.,
2004; Liu et al., 2003). Therefore, we asked whether the
anergic B cells from 564Igi-Rag22/2 mice were able to
respond to CpG. Figure 6A shows the proliferative re-
sponses of 564Igi B cells and nontransgenic C57BL/6
B cells to 10 nM and 50 nM CpG oligodeoxonucleotide
Immunity
434Figure 5. Isotype Skewing of Antibody Production in 564Igi-Rag22/2 Mice
(A) Amounts of total antibody of the indicated isotypes in the sera of 564Igi-Rag22/2; 564Igi-Rag2+/+; nontransgenic C57BL/6, andAicda2/2mice
determined by ELISA. For IgG2a we also tested serum from an IgHa allotype BALB/c mouse as a positive control. Values are averages6 SD for 3
C57BL/6; 3 Aicda2/2; 5 564Igi-Rag2+/+; and 12 564Igi-Rag22/2 mice except in the experiment to measure IgA; 5 C57BL/6, 5 Aicda2/2, 2 564Igi-
Rag2+/+; and 7 564Igi-Rag22/2 mice were used. The experiment shown is representative of at least three independent experiments.
(B) 564Igi-Rag22/2 mice have an anergic surface phenotype. Splenocytes were isolated from a 564Igi-Rag22/2 mouse (solid lines) and a non-
transgenic C57BL/6 mouse (shaded histograms), stained with the indicated antibodies, and analyzed by flow cytometry. Results are represen-
tative of at least two independent experiments.(ODN). Substantial proliferation of 564Igi B cells oc-
curred in response to 10 nM CpG, whereas nontrans-
genic B cells responded poorly to this concentration of
CpG. Both 564Igi and nontransgenic B cells proliferated
well in response to 50 nM CpG. A control GpC ODN failed
to stimulate B cells of either genotype (Figure 6A).
The enhanced response of 564Igi B cells to CpG might
have been due to BCR-mediated endocytosis of the CpG
by the 564 BCR. This would be in addition to the pre-
sumed Ig receptor-independent uptake of CpG ODN,
which is characteristic of non-DNA-reactive B cells. To
determine whether 564 antibody binds to the CpG ODN
used in the proliferation assay, we stained 564 Id+-ex-
pressing B cells with fluorescently labeled CpG ODN
and measured binding by flow cytometry. Figure 6B
shows that CpG ODN stains 564Igi Id+ B cells to a greater
extent than Id2 B cells or nontransgenic B cells.
Thus, despite their anergic phenotype, 564 Id+ B cells
could be activated in vitro through TLR9.
564Igi B Cells Respond Synergistically to the TLR7
Agonist Loxoribine and BCR Ligation
In addition to its ability to bind to nucleosomes (Mohan
et al., 1993), the 564 antibody binds to ssRNA (Gavalchin
et al., 1987), and based on the predominantly cytoplas-
mic staining pattern apparent in Figure 4B, RNA (orRNA-associated proteins) is likely to be the physiologi-
cal ligand. Thus, 564Igi B cells might become activated
in vivo through TLR7. We therefore tested the ability of
564Igi B cells to be activated in vitro by the TLR7 agonist
loxoribine (Akira and Hemmi, 2003; Heil et al., 2003).
Splenocytes from TLR7 wild-type background 564Igi
mice or TLR7-deficient 564Igi littermates were loaded
with CFSE and stimulated for 3 days in vitro with loxor-
ibine alone, a suboptimal concentration anti-IgM alone,
or the combination of loxoribine and anti-IgM. Very few
live (trypan blue excluding) cells were recovered from
cultures of TLR7 wild-type cells cultured either without
stimulation or with 2 mg/ml anti-IgM (Figure 6C). Loxori-
bine treatment rescued some cells, and there was a
synergistic effect of the combination of loxoribine and
anti-IgM on cell survival (Figure 6C). Few live cells
were recovered from cultures of TLR7-deficient cells un-
der any of the conditions (Figure 6C, open histograms).
The extent of B cell proliferation in the loxoribine-treated
and loxoribine plus anti-IgM-treated cultures was deter-
mined by FACS analysis of CFSE staining of viable (PI
excluding) Id+B220+ or Id2B220+ cells (Figure 6D). Id2
B cells proliferated more in response to loxoribine alone
than did Id+ cells (Figure 6D, solid line). There was a
striking increase in proliferation of both Id2 and Id+
cells when cells were treated with the combination of
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(A) Proliferation of 564Igi-Rag22/2 B cells in response to CpG ODN. RBC-depleted splenocytes were loaded with CFSE and cultured for 3.5 days
in medium alone or with the indicated concentration of CpG ODN or control GpC ODN. Cells were stained with anti-CD45 (B220) and CFSE fluo-
rescence in viable B220+ cells determined by flow cytometry. Results are representative of three experiments.
(B) Binding of CpG ODN to 564Igi-expressing B cells. RBC-depleted splenocytes from a C57BL/6 mouse (shaded histogram) and a 564Igi mouse
(unfilled histograms) were stained with 1 mM fluorescein- conjugated ODN 1668, anti-B220, and anti-564Igi-Id. Viable (PI-excluding) lymphocytes
are shown. For the C57BL/6 cells, CpG ODN binding on gated B220+ cells is shown. For the 564Igi cells, CpG binding is shown for gated B220+
564Igi-Id2 cells (dotted line) or B220+ 564Igi-Id+ cells (solid line).
(C) Enhanced cell survival in vitro by treatment of splenocyte cultures with loxoribine and anti-IgM. Splenocytes from a 564Igi-Tlr72/Y mouse
and a 564Igi-Tlr7+/Y littermate were depleted of red blood cells and loaded with CFSE. Cells were incubated for 3.5 days in medium alone, or
with 2 mg/ml anti-IgM, 250 mM loxoribine, or both 2 mg/ml anti-IgM and 250 mM loxoribine. The concentration of live cells in each culture was
determined by counting trypan blue-excluding cells in a hemocytometer. Solid bars, Tlr7+/Y splenocytes; open bars, Tlr72/Y splenocytes.
(D) B cell proliferation in response to loxoribine or loxoribine plus anti-IgM. Proliferation of cells in the cultures described in (C) was determined by
flow cytometry. Viable (PI-excluding) Id2B220+ or Id+B220+ lymphocytes are shown. The result is representative of three experiments.
(E) Induction of T-bet RNA in B cells by loxoribine and CpG ODN. Purified splenic B cells from a C57BL/6 mouse were treated with 250 mM
loxoribine or 250 nM CpG ODN for the indicated times. T-bet RNA expression relative to b-actin was determined by Q-RT-PCR.
(F) T-bet RNA expression is elevated in 564Igi B cells. Amounts of T-bet RNA in sorted CD45 (B220)+ splenocytes from the indicated mice were de-
termined, relative tob-actin, byQ-RT-PCR. T-betexpression relative tob-actinwascalculated for the564Igi-Rag22/2samplesand expressedrelative
to T-bet expression (relative to b-actin expression) in C57BL/6. Error bars are standard deviations. The result is representative of three experiments.loxoribine and anti-IgM (Figure 6D, shaded histograms).
Similar results were obtained when the TLR7 agonist
R848 was used in place of loxoribine (data not shown).
These results revealed a striking ability of BCR cross-
linking to synergize with TLR7 signaling to activate
564Igi B cells.
564Igi+ B Cells Have Elevated T-betGene Expression
In Vivo
The transcription factor T-bet is induced upon B cell ac-
tivation through TLR9 (Liu et al., 2003) and is responsiblefor IgG2a class switch recombination (Gerth et al., 2003;
Lin et al., 2004; Liu et al., 2003; Peng et al., 2002). Given
the predominance of IgG2a Id+ antibodies in 564Igi mice
and the possibility that ssRNA is at least partly respon-
sible for the activation of 564Igi B cells in vivo, we won-
dered whether T-bet expression is induced downstream
of TLR7. Figure 6E shows a time course of T-bet RNA in-
duction, measured by quantitative RT-PCR (Q-RT-PCR)
after treatment of nontransgenic C57BL/6 B cells with
loxoribine. By 48 hr, T-bet was induced to amounts com-
parable to those induced by CpG.
Immunity
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Sera from 564Igi-Tlr72/Y (dotted lines) or 564Igi-Tlr7+/Y (solid lines) were tested by ELISA for Id+ antibodies (left) or total antibodies (right) of the
indicated isotypes. Shown are average values 6 SD for eight (Id+ antibody assay) or seven (total antibody assay) 564Igi-Tlr72/Y mice and nine
564Igi-Tlr7+/Y mice. Asterisks denote statistically significant differences (p < 0.01) determined by a two-tailed Student’s t test. The result is rep-
resentative of two independent experiments.If 564Igi B cells were activated in vivo through either
TLR7 or TLR9, T-bet mRNA expression should have
been elevated in freshly isolated 564 Id+ B cells. We
used Q-RT-PCR to compare T-bet RNA expression in
splenic B cells isolated from 564Igi-Rag22/2 mice to
T-bet expression in nontransgenic C57BL/6 splenic B
cells. As shown in Figure 6F, T-bet RNA expression
was about 5-fold higher in 564Igi+ B cells than in non-
transgenic B cells.
These results are consistent with the idea that 564Igi B
cells become activated in vivo by TLR7 or TLR9 ligation,
which results, among other things, in the induction of
T-bet gene expression.
Production of 564 Id+ IgG2a Was Largely Dependent
on TLR7
The above experiments suggested that 564Igi mice
might produce Id+ antibody as a result of B cell activa-
tion by an antigen able both to bind to the 564 BCR and
to activate either TLR7 or TLR9. To determine whether
TLR7 was important in autoantibody production, we
bred the 564 heavy and light chain genes onto Tlr72/2
mice and measured serum 564 Id+ antibody amounts.
Figure 7 (top), shows that, compared to TLR7 wild-
type littermate controls, there was a dramatic reduction
in serum Id+ IgG2a, IgG2b, IgG3, and IgA but not IgM, in
TLR7-deficient 564Igi mice. This reduction was specific
to 564 Id+ antibody, as shown by the fact that there was
no effect of TLR7 deficiency on total amounts of serum
antibodies of the different isotypes (Figure 7, bottom).
Amounts of Id+ IgG1 could not be measured because
the capture anti-Id is of the IgG1 isotype.
Discussion
Recent studies suggest that dual-specificity ligands that
bind both to the BCR and to intracellular TLRs play a cru-
cial role in activation of self reactive B cells. In these
studies, B cells expressing an anti-IgG2a rheumatoid
factor (RF) proliferated in vitro when treated with im-
mune complexes containing IgG2a and either chromatin
(Leadbetter et al., 2002; Viglianti et al., 2003) or RNA (Lau
et al., 2005). Activation was dependent on binding of the
immune complexes to both the surface anti-IgG2a RFand to TLR9 or TLR7 and required intact TLR signaling.
Similarly, transgenic anti-DNA B cells (but not B cells
with other specificities) were activated, in vitro, by
dsDNA-containing CpG motifs (in this case not part of
immune complexes), again in a TLR9-dependent fashion
(Viglianti et al., 2003). These experiments suggested a
mechanism by which B cells reactive with TLR7 ligands
(ssRNA-containing antigens [Diebold et al., 2004; Heil
et al., 2004]) or TLR9 ligands (dsDNA-containing anti-
gens [Hemmi et al., 2000]) might initiate systemic auto-
immune diseases such as SLE and provided an expla-
nation for why autoantibodies in these diseases often
recognize nucleic acid-containing self-antigens.
Consistent with a role for TLRs in autoimmune dis-
ease, MyD88, an adaptor protein essential for signaling
downstream of multiple TLRs, plays a critical role in au-
toantibody production in MRL-lpr/lpr (Lau et al., 2005)
and FcgRIIB-deficient (Ehlers et al., 2006) mice. Simi-
larly, TLR9 is required for class-switched anti-dsDNA
production in lpr/lpr (Christensen et al., 2005) and
FcgRIIB-deficient (Ehlers et al., 2006) mice, although in
one study, TLR9 protected MRL-lpr/lpr mice from dis-
ease (Wu and Peng, 2006). Even healthy individuals pro-
duce large numbers of B cells reactive with nuclear and
cytoplasmic self-antigens, some of which could pre-
sumably act as TLR7 or TLR9 ligands (Wardemann
et al., 2003). Here we demonstrate that B cells bearing
an RNA-specific BCR (Gavalchin et al., 1987), although
functionally and phenotypically anergic by multiple
criteria, became activated in vivo to class switch and
produce autoantibodies in a largely TLR7-dependent
fashion. This highlights a critical vulnerability of the im-
mune system, even in nonautoimmune-prone animals.
Tolerance induction appeared to occur normally in
564Igi mice. There was extensive receptor editing, and
those B cells that retained expression of the 564 Id
were anergic based on their surface phenotype, exclu-
sion from splenic MZs, and failure to be activated in vitro
by BCR crosslinking or LPS treatment. Yet at least a frac-
tion of these B cells were class-switched and secreted
IgG autoantibody in vivo. Alternatively, despite the ab-
sence of a detectable population of nonanergic Id+ cells
in the spleens of 564Igi mice, it is possible that autoan-
tibody-producing cells were never at any time anergic.
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437The Id+ antibodies produced on both Rag2+/+ and
Rag22/2 backgrounds were predominantly of the
IgG2a isotype, which is the predominant isotype of anti-
bodies eluted from the kidneys of diseased SNF1 mice
(Gavalchin and Datta, 1987). When 564Igi mice were
crossed onto a TLR7-deficient background, there was
a dramatic reduction in amounts of Id+ antibody. Titers
of total antibody were unaffected. This implicates
TLR7 as critical for the activation of Id+ 564Igi B cells.
The simplest explanation for the requirement of TLR7
in autoantibody production is that TLR7 was directly ac-
tivated in 564 Id+ B cells after delivery of ssRNA to the
appropriate compartment by BCR-mediated endocyto-
sis. Consistent with this, 564Igi B cells had elevated
amounts of RNA encoding the transcription factor
T-bet. T-bet is induced by agonists of TLR7 or TLR9 (Fig-
ure 6E; Liu et al., 2003) and plays a direct role in the ini-
tiation of IgG2a class switching (Gerth et al., 2003; Lin
et al., 2004; Liu et al., 2003; Peng et al., 2002). T-bet is
also induced in B cells by the combination of CD40 liga-
tion and IL-12 plus IL-18 (Szabo et al., 2000), but we ob-
served elevated T-bet in B cells from RAG2-deficient
564Igi mice that lack T cells. Further support for the di-
rect activation of 564 Id+ B cells by ssRNA came from
our in vitro studies where 564 Id+ B cells proliferated in
response to the TLR7 agonist loxoribine (Akira and
Hemmi, 2003; Heil et al., 2003) in combination with sub-
optimal concentrations of anti-IgM. Loxoribine alone in-
duced relatively little proliferation of Id+ 564Igi B cells.
This suggests that the BCR normally functions not only
to deliver ssRNA to TLR7 but also to generate signals
that synergize with TLR7-derived signals to induce pro-
liferation. The BCR was also shown to synergize with
TLR signals in B cells activated in vitro through TLR9
(Viglianti et al., 2003). TLR7 may also indirectly induce
autoantibody production by 564Igi B cells by virtue of
its role in pDCs to induce secretion of type I interferon
(Vollmer et al., 2005), which would facilitate activation
of 564Igi B cells.
The synergy between TLR7 and the BCR in Id+ 564Igi
B cells was surprising given that these cells were aner-
gic. In anergic anti-HEL B cells, synergy between the
BCR and TLR9 was completely abolished (Rui et al.,
2003). The discrepancy between this result and ours
could be due to differences between activation by
TLR7 versus TLR9 or could result from differences be-
tween signals generated by BCR ligation with anti-IgM
(our study) versus signals generated by BCR ligation
with a soluble antigen (Rui et al., 2003).
In several other transgenic models, B cells express
a BCR reactive with nucleic acid and could potentially
be activated by dual ligation of the BCR and TLR7 or
TLR9 (reviewed in Fields and Erikson, 2003). Yet in
only one of these systems, in mice containing a targeted
insertion of the 3H9/56R heavy chain gene, is autoanti-
body produced on a nonautoimmune-prone back-
ground. This heavy chain gene binds dsDNA with high
affinity and with an exceptionally large variety of differ-
ent light chains (Radic et al., 1993). On a BALB/c back-
ground, 3H9/56R heavy chain knockin mice produced
IgM but no IgG dsDNA antibody (Fukuyama et al.,
2005; Li et al., 2002). On a C57BL/6 background, both
IgM and IgG dsDNA antibody were produced, but the
IgG titers were very low (Fukuyama et al., 2005). Theselow amounts of IgG anti-DNA were maintained by an
FcgRIIB-dependent checkpoint that limited the accu-
mulation of autoreactive plasma cells (Fukuyama et al.,
2005). This mechanism was evidently overridden in
564Igi mice, which produced large quantities of IgG
564 Id+ antibodies.
So why do 564Igi mice produce high titers of IgG au-
toantibody when similar Ig-transgenic mice do not? It
may be in part due to the C57BL/6 genetic background.
Although C57BL/6 mice do not spontaneously develop
autoimmune disease, they contain genetic loci that
contribute to autoimmune disease in some contexts
(Bygrave et al., 2004; Bolland et al., 2002). Still, other
anti-nucleic acid Ig-transgenic lines maintain tolerance
on a C57BL/6 background (Yachimovich et al., 2002).
The specificity or avidity of the 564 antibody was likely
the determining factor. For example, the physiological
self-antigen of 564 may be present at higher levels
than the self-antigens recognized by other transgenic
BCRs.
Injection of the 564 hybridoma into young, preautoim-
mune SNF1 mice resulted in the rapid development of
kidney disease (Vlahakos et al., 1992). It was not deter-
mined whether this pathogenicity required the autoim-
mune-prone SNF1 background. Here we showed that
in 564Igi mice there were Id+ and IgG2a+ antibodies in
the kidneys along with changes visible by EM consistent
with mesangioproliferative glomerulonephropathies in
human patients. Thus, production of the 564 antibody
was sufficient to cause pathology in nonautoimmune-
prone C57BL/6 mice.
In summary, the 564Igi system demonstrates that
TLR7-dependent processes can result in the activation
of autoreactive B cells to class switch and secrete path-
ogenic antibodies in vivo and lead to renal pathology.
This is likely a result of the dual reactivity of autoantigen
with the BCR and TLR7.
Experimental Procedures
Mice
All experiments with mice were performed in accordance with the
regulations and with the approval of Tufts/NEMC IACUC. C57BL/6
mice were obtained from Jackson Laboratories (Bar Harbor, ME),
RAG2-deficient mice on a C57BL/6 background were obtained
from Taconic (Hudson, NY), AID-deficient mice on a C57BL/6 back-
ground were obtained from Dr. J. Stavnezer (University of Massa-
chusetts Medical School, Worcester, MA) with permission from
Dr. T. Honjo (Kyoto University, Kyoto, Japan), and CMV-Cre trans-
genic mice on a C57BL/6 background were obtained from Dr. J.
Chen (Massachusetts Institute of Technology, Cambridge, MA).
The generation of 564Igi heavy chain targeted transgenic mice has
been described (Fernandez, 2001). 564Igi light chain targeted trans-
genic mice were generated by standard methods. A detailed de-
scription is provided in Supplemental Data.
564Igi mice on a TLR7-deficient background were obtained by
crossing female TLR7 heterozygous mice (Hemmi et al., 2002) with
a male homozygous heavy and light chain 564Igi mouse that was
also C4 deficient (C42/2). All offspring were heterozygous for the
heavy and light chain 564Igi insertions and for C4. Experiments
were performed with male offspring, which were hemizygous for ei-
ther the wild-type (+/Y) or knockout (2/Y) of the X-linked Tlr7 allele.
Flow Cytometry
Cells were stained for flow cytometry according to standard proce-
dures. Propidium iodide (PI) was added just prior to analysis on
a FACScalibur flow cytometer (BD Biosciences). B6-256 anti-Id
was generated as described in Supplemental Data and coupled to
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tions (Invitrogen Molecular Probes). Other fluorochrome-conjugated
antibodies were from BD Biosciences or Southern Biotech and were
generally used at 1 mg/ml. For staining cells with ODN 1668, Alexa
488-conjugated ODN 1668 with a phosphorothioate bond at each
position (Integrated DNA Technologies) was used at a final concen-
tration of 1 mM.
ELISA
For measurements of 564Igi-Id+ antibodies, ELISA plates were
coated with 5 mg/well of purified B6-256 anti-Id hybridoma protein.
Bound serum antibody was detected with 1 mg/ml Alkaline Phospha-
tase (AP)-conjugated isotype-specific goat anti-mouse (Southern
Biotech). For measurement of total serum antibodies of different iso-
types, wells were coated with 1 mg/ml isotype-specific goat anti-
mouse Ig (Southern Biotech) and bound serum antibody detected
with AP-conjugated isotype-specific goat anti-mouse Ig (Southern
Biotech). AP-conjugated antibody was detected with p-nitrophenyl
phosphate (pNPP) (Sigma-Aldrich), and ODs were determined in
a Spectra Max 340 ELISA plate reader (Molecular Devices).
Immunofluorescence Analysis of Spleen Tissue Sections
Tissue sections were processed as previously described (Oliver
et al., 1999). Frozen sections of spleens were stained with
MOMA-1 (rat IgG2a, k; a gift from Dr. Georg Kraal, VU Medical Cen-
ter, Amsterdam, The Netherlands) developed with goat anti-rat
Alexa 647 IgG (Invitrogen), blocked with normal rat serum (Pel-
Freeze), washed, and then stained with a mixture of Alexa 488
mouse anti-564Igi Id (B6-256) and PE-conjugated goat anti-mouse
IgM (Southern Biotech). Stained sections were viewed and photo-
graphed with a Leica DMRB microscope with a Hamamatsu
C4742-95 camera and Openlab software.
Electron, Immunofluorescence, and Light Microscopy Analysis
of Kidney Sections
Tissue samples for electron microscopy were first fixed in Trump’s
fixative for 30 min and then post-fixed in 2% aqueous osmium te-
troxide for 20 min at room temperature. The fixed tissue was washed
in distilled water twice and en block stained in saturated uranyl ac-
etate in 50% ethanol for 15 min. It was then dehydrated into absolute
ethanol, placed in two changes of propylene oxide for 5 min each,
and transferred into propylene oxide epoxy resin mixture 1:1 for
2 min and finally into epoxy resin. The cured epoxy blocks were sec-
tioned on an LKB ultra microtome with appropriate glomerular sam-
ples thin-sectioned at 30–40 nm and picked up on copper grids. The
grids were stained with uranyl acetate and lead citrate. The samples
were examined and photographed in a Philips EM 20.
Fresh kidney samples for immunofluorescence studies were
frozen in OCT and 4 mm sections cut on a cryostat and mounted
on glass slides. The sections were air-dried for 1 hr, dehydrated in
PBS, and incubated with primary fluorescein-conjugated antibody
solution 1/200 dilution for 1 hr at room temperature. The sections
were rinsed in PBS, mounted in Aquamount, and examined and
photographed in a Zeiss fluorescence microscope.
Kidneys were removed, fixed in 10% buffered formalin, and em-
bedded in paraffin. 5 mm paraffin sections were stained with periodic
acid-Schiff (PAS) and evaluated by light microscopy in a blind man-
ner as previously described (Vlahakos et al., 1992).
Quantitative RT-PCR
Total RNA was prepared with TRIzol reagent (Invitrogen) from
splenic B220+ cells sorted on a MoFlo cell sorter (Dako Cytomation).
RNA was subsequently repurified with RNeasy columns (Qiagen).
cDNA synthesis was performed on 5-fold serial dilutions of RNA
with Iscript cDNA synthesis kit (Bio-Rad). Real-time PCR was per-
formed in triplicate for each cDNA reaction with Applied Biosystems
TaqMan reaction mix according to the manufacturer’s instructions.
Further details about the Q-RT-PCR are available in Supplemental
Data.
Proliferation Assays
Disaggregated splenocytes were passed through a nylon cell
strainer and depleted of red blood cells (RBC) by treatment with
Tris-NH4Cl-BSA at 4
C for 4 min. Cells were washed and resus-pended in complete medium (RPMI 1640 plus sodium pyruvate,
HEPES, glutamine, 2-mercaptoethanol, nonessential amino acids,
and 10% fetal calf serum [FCS]) or DPBS with 5% FCS. To load cells
with CFSE, they were washed and resuspended in serum-free RPMI
1640 at 2.5 3 106 cells/ml. CFSE in DMSO was added to a final con-
centration of 5 mM and cells incubated at room temperature for
5 min. The reaction was stopped by the addition of FCS to 20%.
Cells were washed twice and resuspended in complete medium at
1 3 106 cells/ml. Cells were treated with immunostimulatory ODN
1668 (tccatgacgttcctgatgct) or control ODN 1720 (tccatgagcttcct
gatgct), both with a phosphorothioate bond at each position and
HPLC purified, obtained from Integrated DNA Technologies. Both
had less than 0.1 endotoxin units/ml by the kinetic limulus test (Cam-
brex). LPS stimulations were performed with E. coli LPS (Sigma-
Aldrich). Loxoribine (InVivogen) was used at a concentration of
250 mM. F(ab0)2 goat anti-mouse IgM m-chain specific was from
Jackson Immunoresearch. After culture, cells were harvested,
resuspended in FACS staining buffer, and stained with fluoro-
chrome-conjugated antibodies for FACS analysis as described
above.
Calcium Flux Assays
RBC-depleted splenocytes were washed once in DPBS with 5%
FCS and resuspended in DPBS with 5% FCS at 5 3 106 cells/ml.
Indo-1-AM (Invitrogen) was added to a final concentration of 1 mM
from a 1 mM stock in DMSO. Cells were incubated at 37C for
30 min, washed twice, and resuspended in DPBS with 5% FCS
and stained with fluorochrome-conjugated antibodies. 0.5 ml ali-
quots of cells at 5 3 106/ml were analyzed for Ca2+ flux on a MoFlo
cell sorter (Dako Cytomation). Cells were stimulated with F(ab0)2
goat anti-mouse IgM, m chain specific (Jackson Immunoresearch).
Immunofluorescence Staining of HEp-2 Cells
Fixed human HEp-2 cells (Antibodies Inc.) were stained with mouse
serum according to the manufacturer’s instructions, except that the
secondary antibody was either FITC-conjugated F(ab0)2 goat anti-
mouse IgG (Jackson Immunoresearch) or FITC-anti-mouse IgG2a
(Southern Biotech). Slides were mounted with ProLong Gold anti-
fade reagent (Invitrogen) and digitally photographed with a Nikon
E400 fluorescence microscope.
Supplemental Data
Supplemental Data include three figures and Supplemental Results
and Experimental Procedures and can be found with this article
online at http://www.immunity.com/cgi/content/full/25/3/429/DC1/.
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